Compare WIA & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | ARCT |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.8M | 194.1M |
| IPO Year | N/A | N/A |
| Metric | WIA | ARCT |
|---|---|---|
| Price | $8.24 | $6.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.67 |
| AVG Volume (30 Days) | 39.2K | ★ 846.7K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $97,601,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.56 | $5.85 |
| 52 Week High | $8.91 | $24.17 |
| Indicator | WIA | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 35.29 |
| Support Level | $8.19 | $7.04 |
| Resistance Level | $8.29 | $7.76 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | -0.00 | 0.30 |
| Stochastic Oscillator | 16.67 | 26.65 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.